The use of new imaging techniques to predict tumour response to therapy

Vanessa N Harry, Scott I Semple, David E Parkin, Fiona J Gilbert

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Imaging of tumour response to therapy has steadily evolved over the past few years as a result of advances in existing imaging modalities and the introduction of new functional techniques. The use of imaging as an early surrogate biomarker of response is appealing, because it might allow for a window of opportunity during which treatment regimens can be tailored accordingly, depending on the expected response. The clinical effect of this would ultimately result in a reduction in morbidity and undue costs. The aim of this review is to describe the potential of various new imaging techniques as biomarkers of early tumour response. We have reviewed the literature and identified studies that have assessed these techniques, such as diffusion-weighted MRI, dynamic contrast-enhanced MRI, magnetic resonance spectroscopy, and 18-fluorodeoxyglucose-PET as early response indicators, and highlight the current clinical awareness of their use.
Original languageEnglish
Pages (from-to)92-102
Number of pages11
JournalThe Lancet Oncology
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Diffusion Magnetic Resonance Imaging
Tumor Biomarkers
Magnetic Resonance Spectroscopy
Biomarkers
Morbidity
Costs and Cost Analysis
Neoplasms
Therapeutics

Keywords

  • positron emission tomography
  • cell lung cancer
  • standardized uptake value
  • functional diffusion map
  • advanced breast cancer
  • F-18 fluorodeoxyglucose uptake
  • advanced rectal carinoma
  • monitoring early response
  • contrast enhanced MRI
  • cervical cancer

Cite this

The use of new imaging techniques to predict tumour response to therapy. / Harry, Vanessa N; Semple, Scott I; Parkin, David E; Gilbert, Fiona J.

In: The Lancet Oncology, Vol. 11, No. 1, 01.2010, p. 92-102.

Research output: Contribution to journalArticle

Harry, Vanessa N ; Semple, Scott I ; Parkin, David E ; Gilbert, Fiona J. / The use of new imaging techniques to predict tumour response to therapy. In: The Lancet Oncology. 2010 ; Vol. 11, No. 1. pp. 92-102.
@article{96720ebdd9c249a9a79f2b54826d3311,
title = "The use of new imaging techniques to predict tumour response to therapy",
abstract = "Imaging of tumour response to therapy has steadily evolved over the past few years as a result of advances in existing imaging modalities and the introduction of new functional techniques. The use of imaging as an early surrogate biomarker of response is appealing, because it might allow for a window of opportunity during which treatment regimens can be tailored accordingly, depending on the expected response. The clinical effect of this would ultimately result in a reduction in morbidity and undue costs. The aim of this review is to describe the potential of various new imaging techniques as biomarkers of early tumour response. We have reviewed the literature and identified studies that have assessed these techniques, such as diffusion-weighted MRI, dynamic contrast-enhanced MRI, magnetic resonance spectroscopy, and 18-fluorodeoxyglucose-PET as early response indicators, and highlight the current clinical awareness of their use.",
keywords = "positron emission tomography, cell lung cancer, standardized uptake value, functional diffusion map, advanced breast cancer, F-18 fluorodeoxyglucose uptake, advanced rectal carinoma, monitoring early response, contrast enhanced MRI, cervical cancer",
author = "Harry, {Vanessa N} and Semple, {Scott I} and Parkin, {David E} and Gilbert, {Fiona J}",
year = "2010",
month = "1",
doi = "10.1016/S1470-2045(09)70190-1",
language = "English",
volume = "11",
pages = "92--102",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - The use of new imaging techniques to predict tumour response to therapy

AU - Harry, Vanessa N

AU - Semple, Scott I

AU - Parkin, David E

AU - Gilbert, Fiona J

PY - 2010/1

Y1 - 2010/1

N2 - Imaging of tumour response to therapy has steadily evolved over the past few years as a result of advances in existing imaging modalities and the introduction of new functional techniques. The use of imaging as an early surrogate biomarker of response is appealing, because it might allow for a window of opportunity during which treatment regimens can be tailored accordingly, depending on the expected response. The clinical effect of this would ultimately result in a reduction in morbidity and undue costs. The aim of this review is to describe the potential of various new imaging techniques as biomarkers of early tumour response. We have reviewed the literature and identified studies that have assessed these techniques, such as diffusion-weighted MRI, dynamic contrast-enhanced MRI, magnetic resonance spectroscopy, and 18-fluorodeoxyglucose-PET as early response indicators, and highlight the current clinical awareness of their use.

AB - Imaging of tumour response to therapy has steadily evolved over the past few years as a result of advances in existing imaging modalities and the introduction of new functional techniques. The use of imaging as an early surrogate biomarker of response is appealing, because it might allow for a window of opportunity during which treatment regimens can be tailored accordingly, depending on the expected response. The clinical effect of this would ultimately result in a reduction in morbidity and undue costs. The aim of this review is to describe the potential of various new imaging techniques as biomarkers of early tumour response. We have reviewed the literature and identified studies that have assessed these techniques, such as diffusion-weighted MRI, dynamic contrast-enhanced MRI, magnetic resonance spectroscopy, and 18-fluorodeoxyglucose-PET as early response indicators, and highlight the current clinical awareness of their use.

KW - positron emission tomography

KW - cell lung cancer

KW - standardized uptake value

KW - functional diffusion map

KW - advanced breast cancer

KW - F-18 fluorodeoxyglucose uptake

KW - advanced rectal carinoma

KW - monitoring early response

KW - contrast enhanced MRI

KW - cervical cancer

U2 - 10.1016/S1470-2045(09)70190-1

DO - 10.1016/S1470-2045(09)70190-1

M3 - Article

VL - 11

SP - 92

EP - 102

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 1

ER -